NewLink Genetics Corporation (NLNK) Coverage Initiated at Bank of America Corporation

Equities researchers at Bank of America Corporation began coverage on shares of NewLink Genetics Corporation (NASDAQ:NLNK) in a research report issued on Friday, October 13th, MarketBeat.com reports. The brokerage set a “buy” rating and a $22.00 price target on the biotechnology company’s stock. Bank of America Corporation’s target price suggests a potential upside of 118.25% from the company’s current price.

Several other research analysts have also recently commented on the stock. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $8.00 to $22.00 in a report on Friday, September 8th. ValuEngine cut shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Stifel Nicolaus raised their target price on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Zacks Investment Research cut shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Finally, Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $25.83.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 10.08 on Friday. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17. The company’s market cap is $296.56 million. The company has a 50-day moving average of $11.21 and a 200-day moving average of $11.01.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The company had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. On average, equities research analysts predict that NewLink Genetics Corporation will post ($2.73) EPS for the current year.

WARNING: “NewLink Genetics Corporation (NLNK) Coverage Initiated at Bank of America Corporation” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/22/newlink-genetics-corporation-nlnk-research-coverage-started-at-bank-of-america-corporation.html.

In related news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The stock was acquired at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the transaction, the insider now directly owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Driehaus Capital Management LLC purchased a new stake in shares of NewLink Genetics Corporation in the first quarter worth approximately $5,127,000. Northwest Wealth Management LLC raised its position in NewLink Genetics Corporation by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock valued at $426,000 after acquiring an additional 1,740 shares in the last quarter. Prudential Financial Inc. bought a new position in NewLink Gene

Several other research analysts have also recently commented on the stock. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $8.00 to $22.00 in a report on Friday, September 8th. ValuEngine cut shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Stifel Nicolaus raised their target price on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Zacks Investment Research cut shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Finally, Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $25.83.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 10.08 on Friday. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17. The company’s market cap is $296.56 million. The company has a 50-day moving average of $11.21 and a 200-day moving average of $11.01.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The company had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. On average, equities research analysts predict that NewLink Genetics Corporation will post ($2.73) EPS for the current year.

WARNING: “NewLink Genetics Corporation (NLNK) Coverage Initiated at Bank of America Corporation” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/22/newlink-genetics-corporation-nlnk-research-coverage-started-at-bank-of-america-corporation.html.

In related news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The stock was acquired at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the transaction, the insider now directly owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Driehaus Capital Management LLC purchased a new stake in shares of NewLink Genetics Corporation in the first quarter worth approximately $5,127,000. Northwest Wealth Management LLC raised its position in NewLink Genetics Corporation by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock valued at $426,000 after acquiring an additional 1,740 shares in the last quarter. Prudential Financial Inc. bought a new position in NewLink Genetics Corporation during the first quarter valued at approximately $443,000. Bank of America Corp DE raised its position in NewLink Genetics Corporation by 361.8% during the first quarter. Bank of America Corp DE now owns 31,911 shares of the biotechnology company’s stock valued at $769,000 after acquiring an additional 25,001 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in NewLink Genetics Corporation during the first quarter valued at approximately $3,453,000. 54.77% of the stock is owned by institutional investors and hedge funds.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply